216 Shares in Stryker Co. (NYSE:SYK) Bought by Wingate Wealth Advisors Inc.

Wingate Wealth Advisors Inc. bought a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 216 shares of the medical technology company’s stock, valued at approximately $78,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dunhill Financial LLC lifted its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Stryker in the third quarter valued at $36,000. Activest Wealth Management bought a new position in shares of Stryker in the fourth quarter valued at $36,000. Crews Bank & Trust bought a new position in shares of Stryker during the fourth quarter valued at about $39,000. Finally, Hara Capital LLC bought a new position in shares of Stryker during the third quarter valued at about $42,000. 77.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Stryker Trading Up 0.2 %

Stryker stock opened at $392.15 on Tuesday. The firm’s 50 day moving average price is $377.23 and its 200-day moving average price is $365.14. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The stock has a market cap of $149.50 billion, a P/E ratio of 50.53, a PEG ratio of 2.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company earned $3.46 earnings per share. On average, equities analysts predict that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s dividend payout ratio is presently 43.30%.

Analyst Ratings Changes

A number of research firms recently weighed in on SYK. Needham & Company LLC reissued a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Wells Fargo & Company raised their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Canaccord Genuity Group raised their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Finally, UBS Group lifted their target price on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.